Medi Caps Ltd Q1 2026 Results

Consolidated net loss of ₹2.23 crore on revenue of ₹2.79 crore for the quarter ended June 30, 2026.
Standalone net loss of ₹0.59 crore on revenue of ₹0.10 crore.

Reader Takeaway: Persistent losses across segments contrast with board restructuring; profitability challenges remain.

What just happened

Medi-Caps Limited announced its financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹2.79 crore, alongside a consolidated net loss of ₹2.23 crore. On a standalone basis, revenue was ₹0.10 crore, with a net loss of ₹0.59 crore.

Why this matters

These results highlight ongoing profitability concerns for Medi-Caps. The net loss, both consolidated and standalone, indicates that the company is currently spending more than it earns. Investors will be looking for signs of a turnaround and improved financial performance in future quarters.

The backstory

The financial performance for the quarter includes contributions from both Pharma and Real Estate segments. The Pharma division reported a loss of ₹1.64 crore, and the Real Estate division reported a loss of ₹0.59 crore. The company's wholly-owned subsidiary, Medgel Private Limited, also contributed to the consolidated figures, reporting a net loss of ₹2.23 crore.

What changes now

Key management changes were announced, including the re-appointment of Mr. Alok K. Garg as Chairman cum Managing Director and the appointment of Mrs. Saloni Garg as Additional Director and Whole Time Woman Director. Mr. Akshit Garg has been appointed as the Chief Financial Officer (CFO). These changes aim to provide strategic direction and financial oversight.

Risks to watch

The primary risk for investors remains the company's inability to achieve profitability. The sustained losses in core operating segments and the subsidiary present a significant challenge. The upcoming Annual General Meeting on September 22, 2026, will be a crucial event for shareholders.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

For the quarter ended June 30, 2026:

• Consolidated Revenue: ₹2.79 crore
• Consolidated Net Loss: ₹2.23 crore
• Standalone Revenue: ₹0.10 crore
• Standalone Net Loss: ₹0.59 crore
• Pharma Segment Loss: ₹1.64 crore
• Real Estate Segment Loss: ₹0.59 crore

What to track next

Investors should closely monitor the company's future financial results, focusing on revenue growth and efforts to reduce losses. Developments related to the company's segments and the outcomes of the Annual General Meeting will also be important.